Skip links

MABPRO, a.s.

We are building an immunotherapy platform and companion diagnostics for aggressive, hypoxic tumors using Carbonic Anhydrase IX (CA IX) as the therapeutic target and mechanism of action.

Discover More

Mission & Vision

To fill the gap in the treatment of oncology diseases / hypoxic tumours with poor prognosis.

To bring hope and increase survival in patients unresponsive to standard oncology treatments.

To deliver new targeted therapies aligned with personalized medicine to improve patient outcomes.

Targeted Tumor Types

Tumors expressing Carbonic Anhydrase IX.

Advanced Patient Stratification

MABPRO, a.s. coordinates a major, multi-partner, bioinformatics project designed to develop advanced patient stratification capabilities for personalized immunotherapy treatment.

Mechanism of action

CA9hu-1 and CA9hu-2: TWO CUSTOM DESIGNED HUMANIZED IgG1 ANTIBODIES.

CA IX

Bind to the extracellular domain of CA IX and attract NK and T cells.

CA IX

Inhibit CA IX and alter the tumor microenvironment by increasing extracellular pH.

CA IX

Inhibit CA IX and decrease intracellular pH, reducing mTOR signaling.

More Details

Seal of Excellence

Recognized as a high-quality project proposal in a highly competitive evaluation process. Awarded with the Horizon Europe Seal of Excellence.

See the certificate

Cancer Immunotherapy Platform For Hypoxic Tumors

What they said about us

EIC Accelerator Evaluation Quotes

Personalized immunotherapy for hypoxic tumors

Find Out More